Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?

IF 2.8 3区医学 Q2 UROLOGY & NEPHROLOGY

Seminars in nephrology Pub Date : 2023-05-01 DOI:10.1016/j.semnephrol.2023.151430

Peter Rossing MD , Marie Frimodt-Møller MD , Frederik Persson MD

引用次数: 0

Abstract

Approximately 30–40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.

查看原文本刊更多论文

精准医学和/或基于生物标志物的T2DM治疗：准备好进入黄金时段了吗？

大约30-40%的2型糖尿病患者发展为慢性肾脏疾病。其特征是血压升高，肾功能下降，心血管发病率和死亡率增加。必须定期评估蛋白尿增加和估计肾小球功能下降，以诊断肾病。新的生物标志物可能有助于早期诊断，并提供有关未发现病理学的信息，从而支持早期精确干预以获得最佳效益。已经提出了许多生物标志物，但尚未在临床实践中实施。iI未来这种双标记物可能为个性化治疗铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nephrology 医学-泌尿学与肾脏学

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Seminars in Nephrology is a timely source for the publication of new concepts and research findings relevant to the clinical practice of nephrology. Each issue is an organized compendium of practical information that serves as a lasting reference for nephrologists, internists and physicians in training.